Many human leukemias are characterized by chromosomal translocations yielding hybrid RNAs capable of encoding fusion chimeric proteins. The unique amino acid sequences found in these oncogenic fusion proteins represent true tumor-speclfc antigens that are potentially immunogenic. Although these leukemia-specific fusion proteins have an intracellular location, they might be recognized immunologically by T lymphocytes if peptides derived from the unique sequences are capable of presentation by the major histocompatibility complex (MHC) molecules on leukemic cells. The ability of a series of synthetic peptides corresponding to the junctional sequences of chronic myelogenous leukemia (CMLkderived bcr-ab1 and acute promyelocytic leukemia (APLI-derived PML-RARa fusion proteins to bind to purified class I molecules was studied, A series of 152 peptides 8,9, 10, and 11 amino acids in length, spanning the b3a2 and OST HUMAN LEUKEMIAS are associated with chromosomal abnormalities resulting from genetic mutations or translocations that can create new hybrid genes capable of expressing mutated or fused proteins. The encoded abnormal fusion proteins are characterized by a joining region segment composed of a unique sequence of amino acids that is potentially immunogenic.
of APL patient^.^.^ As with CML, both APL proteins contain an unique epitope consisting of the site of fusion in addition to a new amino acid.
Human T-cell recognition of tumor-associated antigens has been shown for human melanoma antigen^^.^ as well as for a single point mutation in ras, resulting in a single amino acid change.' Specific human CD4 T-cell responses have been generated in vitro against the PML-RARa fusion protein found in APL cells' and in vivo against B-cell lymphoma Ig idiotypes.' In addition, Chen et all0 have shown that immunization of mice with synthetic peptides corresponding to the joining region of bcr-ab1 elicited peptide specific, CD4+, restricted T cells. These interesting findings provide evidence that CML-derived peptides can be presented by the murine class I1 major histocompatibility complex (MHC) but are not relevant for predicting similar results with human HLA proteins. The pairs of proteins found in CML and APL represent some of the most obvious targets for an immunologic approach to the treatment of these leukemias and serve as a model for this approach in other neoplasms. Although the bcr-ab1 and PML-RARa proteins have an intracellular location, enzymatic degradation products of these fusion proteins could be presented on the cell surface as short peptides, 8 to 25 amino acids in length, within the cleft of HLA molecules and potentially may be recognized by T cells. These peptides are derived by intracellular processing of exogenous and endogenous proteins as part of the antigen presentation pathway."
The amino acid motifs responsible for specific peptide binding to HLA class I molecules have been determined for the common HLA class I types by the use of the analysis of acideluted naturally processed peptides and by the use of cell lines defective in intracellular peptide loading and proce~sing.'~"~ More recently, a quantitative molecular radiobinding assay for the analysis of peptide binding to purified HLA class I molecules has been developed by Ruppert et al. '5 To develop a vaccine strategy for APL and CML, the first two important questions are whether oncogenic fusion For personal use only. on August 30, 2017. by guest www.bloodjournal.org From proteins contain suitable amino acid sequences and appropriate anchor motifs for binding to class I molecules and whether these breakpoint peptides can bind with sufficiently high affinity to the groove of HLA class I molecules; this activity is necessary to induce a leukemia-specific T-cell response. In this study, we analyzed the ability of a series of synthetic peptides corresponding to the junctional sequences of bcr-ab1 and PML-RARa proteins to bind to purified human class I molecules. The rationale for this approach was twofold. (1) Breakpoint-spanning peptides able to bind class I molecules could be potential candidate antigens for active immunotherapy against these leukemias. (2) Evidence that unique tumor-specific breakpoint sequences are not be presented in the context of HLA molecules would provide a molecular basis for immune nonresponsiveness to abnormal intracellular fusion proteins in leukemic cells. 
MATERIALS AND METHODS

Peptides
Purijcation of HLA Class I Molecules
HLA class I molecule purification was performed according to the procedure recently described by Ruppert et a l l 5 and Sidney et al. '6 Briefly, after preparation of detergent lysed extracts from Epstein-Barr virus (EBV) cell lines homozygous for each HLA type used in the study, HLA molecules were purified by affinity chromatography. HLA molecules were concentrated and purity was determined to be greater than 90% by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
MHC Binding Assay
Peptide binding to purified MHC class I molecules was measured as de~cribed.'~.'~ Briefly, the assay is based on the inhibition of binding of the radiolabeled standard peptide described above to detergent-solubilized purified MHC molecules. HLA concentrations (about 10 nmoVL) yielding 15% bound standard peptide were used in the inhibition assay. A serial dilution of CML or APL breakpointspanning peptide (30 ,umol/L to 1 nmol/L) were incubated together with 5 nmol/L of the radiolabeled standard peptide and matched appropriate HLA molecule. The percentage of MHC-bound radioactivity was then determined by gel filtration, and the inhibition was calculated.
RESULTS
Analysis of HLA Class I Motifs CML. A total of 76 possible peptide sequences spanning 8, 9, 10, or 11 amino acids of the b2a2 and b3a2 junctional regions of bcr-ab1 proteins were analyzed for motifs with potential to bind to the most common HLA-A class I molecules (Al, A2.1, A3.2, A l l , andA24) andHLA-B molecules in which anchor motifs are known (B7, B8, and B27).'7-'3 These HLA types are amongst the predominant types expressed in the US population. The sequences of all peptides 11 amino acids in length encompassing the b3a2 breakpoints are shown (Fig 1A) . Series of peptides 8, 9, and 10 amino acids in length were included in the analysis for MHC binding as well. The sequence of the b2a2 breakpoint is also shown (Fig 1B) . Based on their sequences alone, 21 bcr-ab1 peptides (10 for the b2a2 breakpoint and 11 for the b3a2 breakpoint) of 8, 9, or 10 amino acids in length were predicted to have the potential of binding one or more class I molecule (Table 1) .
APL. The 76 peptides of appropriate lengths spanning PML-RARa A and B fusion regions were also studied. The sequences surrounding the two breakpoints are shown (Fig  1 C and D) . Peptides 8, 9, 10, and 11 amino acids in length were analyzed for the presence of specific HLA class I anchor motifs. Two peptides from PML-RARa A and 2 from PML-RARa B breakpoint were considered potentially suitable for class I binding based on the presence of specific motifs ( Table 2) .
Peptide Synthesis and MHC Binding Assay
CML. The CML peptides with appropriate motifs were synthesized and tested for binding to purified HLA molecules. Among the 11 b3a2 peptides selected for HLA motifs, 6 displayed significant binding affinities for both HLA A3.2 and A l l (Table 1 ). These two class I molecules have many similarities in structure and share similar binding motifs." The peptide ATGFKQSSK bound with higher affinity (97 nmol/L to achieve 50% inhibition) to HLA A l l and with intermediate affinity (300 nmol/L required for 50% inhibition) to HLA A3.2. In contrast, peptide KQSSKALQR showed high-affinity binding to HLA A3.2 (43 nmol/L for 50% inhibition) and had intermediate affinity for HLA A1 1 (273 nmol/L). A third peptide HSATGFKQSSK was found to bind with intermediate affinity to both A3.2 and A1 1 (400 nmol/L and 125 nmol/L for 50% inhibition, respectively).
The remaining three peptides bound A3.2 or A1 1 much more weakly (>500 nmol/L to <6 pmol/L to achieve 50% inhibition). In addition, two b3a2 peptides bound to HLA B8 with intermediate (GFKQSSKAL, 190 nmol/L) or low affinity.
None of the 10 peptides belonging to the b2a2 breakpoint showed high or intermediate relative binding affinity (5500 nmol/L affinity) for any of the purified HLA class I molecules used in the binding assay. Two peptides displayed low affinity for HLA A1 1 or B8, respectively.
APL. Four APL sequences that contained motifs with potential for HLA binding to HLA A2.1 were synthesized and assayed as described. None of these peptides showed appreciable binding affinity for HLA A2.1 in the competitive assays (B50 pmol/L for 50% inhibition; Table 2 ).
DISCUSSION
In this study we found that, among all 76 possible peptides spanning the breakpoints of the CML fusion proteins, there were 21 peptide sequences with potential HLA binding motifs; four peptides, all derived from the b3a2 breakpoint of bcr-abl, bound with either intermediate and high affinity to purified HLA A3.2, A1 1, and B8 molecules. This is the first time that leukemia-oncogene derived breakpoint peptides have been shown to be able to bind HLA class I molecules and may provide a rationale to develop a therapeutic vaccine. 
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The bcr-ab1 and PML-RARu breakpoint-derived peptides are an ideal model system in which to explore active specific immunotherapy of cancer. These peptides represent potential antigens by virtue of the novel sequence of the junctional regions. Second, the sequences are found only in cells belonging to the leukemic clone. Because both fusion proteins are involved in the leukemogenic events in these respective leukemias, antigen-negative clonogenic cells are likely to be rare; thus, escape by protein (antigen) loss is not probable. Finally, development of an active response specific to the antigen is not likely to be harmful, because the target is unique to the leukemia cells.
Because of their intracellular location, these fusion proteins may be processed and presented on the cell surface via the HLA class I molecule pathway and thus may be accessible to cytotoxic CD8 cells. Screening these peptides for HLA class I anchor motifs and testing them for effective HLA binding represents a first necessary step in the analysis of their value as potential antigens. It is encouraging to note that four different potential vaccine candidates have been identified in the course of these experiments. Future studies will evaluate the capacity of these HLA binding peptides to elicit class I-restricted CD8 cells.
A different approach was recently tested by Cullis et a124 in which 18 peptides spanning the junctional sequences of the b2a2 and b3a2 protein were tested for their ability to rescue the expression of the class I alleles in two human cell lines LBL 721.174 (T2; HLA A2, B5) and BM 36.1 (HLA Al, B35). These cells are defective in intracellular peptide loading of class I molecules. None of the bcr-ab1 peptides enhanced HLA A2 or HLA B35 allele expression when compared with allele-specific control peptides. The investigators concluded that none of the CML peptides satisfies the known peptide-binding motifs for these alleles. Our findings support their negative results with HLA A2 molecules and show that HLA Al, A24, B7, and B27 are also incapable of binding to CML peptides.
Recent data support the hypothesis that peptides that bind to HLA with moderate to high affinity are those that are capable of T-cell stimulation after natural processing and cell surface presentation within the cleft of the appropriate HLA. The importance of these moderate-to high-affinity 
A dash indicates that the value was greater than 30 pmoVL. The unique junctional amino acid is shown in bold. HLA A1 was not tested because peptide sequences with the appropriate motif were not found.
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peptides for effective stimulation of T cells is supported by additional evidence. (1) Naturally processed peptides that are found on the surface of live cells bound to HLA molecules typically have an affinity in the range described here for the CML peptides." (2) Only peptides that bind to HLA with affinities in this range were able to induce a cytotoxic response in vitro and in vivo m o d e l~?~~~~ (3) Peptides from the intracellular protein MAGE in melanoma identified by motifs as described above were found to be naturally expressed in the context of appropriate HLA molec~les?~ Although the binding of leukemia fusion point peptides to HLA is a necessary step in the development of immunity to these antigens, it may not be sufficient. Although both APL and CML cells express high levels of HLA-A (D. A. Scheinberg, unpublished data), appropriate T-cell presentation of breakpoint peptides has not yet been proven in our studies. The amounts of peptide presented in the context of the HLA molecules on the leukemia cells or the type of processing of the fusion oncogenic protein (P210) may be found to be insufficient for inducing a T-cell response. Alternatively, relevant T-cell receptor specificities might be determined to be functionally absent because of induction of Tcell tolerance.
It is of considerable interest that no potential peptide antigens were found for APL or the CML fusion-peptide b2a2. This finding strongly suggests that specific CD8 responses restricted by the HLA types studied are unlikely in patients with APL or in the patients with CML and b2a2 breakpoint. However, Gambacorti-Passerini et a18 have shown that cytotoxic CD4 cells can be generated in vitro to longer APLderived fusion peptides. Therefore, specific immunity may still be possible via class I1 responses. In addition, other HLA A, B, and C class I types that have not been studied as yet may be capable of presenting specific APL-or CMLderived peptides.
Recent studies in patients with CML who have relapsed after an allogeneic bone marrow transplant have shown that infusion of donor T cells can reinduce durable complete Finally, if the specific binding of HLA A3.2, A1 1, and B8 subtypes to b3a2-derived peptides is reflected in vivo by class I-specific CD8+ cells capable of controlling leukemia proliferation, the incidence of CML in populations carrying these HLA alleles may be influenced. Moreover, the favorable response to immunotherapies such as a interferon of only a subset of patients might also be HLA associated. Population studies with attention to the type of breakpoint (b3a2 v b2a2) and HLA subtype would be useful in elucidating this issue.
